(Bloomberg) -- Roche Holding AG, the world's biggest
maker of cancer medicines, may pay as much as $1 billion for
rights to Alnylam Pharmaceuticals Inc. technology that may allow
the companies to find new tumor, liver and breathing treatments.
Alnylam will get a cash payment of $288.5 million and will
sell Roche about 2 million shares for $42.5 million. The stock
represents just less than a 5 percent stake in Alnylam, the
Basel, Switzerland-based company said today. Roche will also get
Cambridge, Massachusetts-based Alnylam's German research site.
Read more at Bloomberg Stocks News
maker of cancer medicines, may pay as much as $1 billion for
rights to Alnylam Pharmaceuticals Inc. technology that may allow
the companies to find new tumor, liver and breathing treatments.
Alnylam will get a cash payment of $288.5 million and will
sell Roche about 2 million shares for $42.5 million. The stock
represents just less than a 5 percent stake in Alnylam, the
Basel, Switzerland-based company said today. Roche will also get
Cambridge, Massachusetts-based Alnylam's German research site.
Read more at Bloomberg Stocks News
No comments:
Post a Comment